Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Israel - English - Ministry of Health

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - English - Ministry of Health

bioavenir ltd, israel - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - letrozole farmoz tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole farmoz is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - English - Ministry of Health

perrigo israel agencies ltd - letrozole 2.5 mg - film coated tablets - letrozole - • femozol (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer . • femozol is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy .• extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy .• adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer .

Israel - English - Ministry of Health

inovamed ltd - letrozole 2.5 mg - film coated tablets - letrozole - for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy.adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - English - Ministry of Health

dexcel ltd, israel - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - letrozole - dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. letrozole - dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - English - Ministry of Health

rafa laboratories ltd - letrozole 2.5 mg - film coated tablets - letrozole - letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.